Summary of Oncolytics Biotech Key Opinion Leader Webinar Company and Industry - **Company**: Oncolytics Biotech - **Industry**: Oncology, specifically focusing on pancreatic cancer and other gastrointestinal cancers Core Points and Arguments 1. **Introduction of Pelareorep**: Pelareorep is an oncolytic virus that selectively targets cancer cells and is administered intravenously, making it easier for widespread application compared to other oncolytic viruses that require intratumoral administration [6][7][8] 2. **Efficacy in Pancreatic Cancer**: Pelareorep has shown strong efficacy signals in pancreatic cancer, with a 62% overall response rate observed in clinical studies, which is significantly higher than traditional chemotherapy combinations [15][34] 3. **Unmet Need in Pancreatic Cancer**: Pancreatic cancer is the 10th most common cancer but the second leading cause of cancer death, highlighting the urgent need for effective treatments [10][11] 4. **Current Treatment Landscape**: Standard treatments include gemcitabine and FOLFIRINOX, with limited overall survival rates. Pelareorep combined with chemotherapy has shown improved survival rates compared to historical controls [12][13][22] 5. **Safety Profile**: Over 1,100 patients have been treated with Pelareorep, showing a favorable safety profile with mild side effects such as flu-like symptoms, indicating it is well-tolerated [66][70] 6. **Combination Therapy Potential**: Pelareorep can be combined with various chemotherapy regimens and checkpoint inhibitors, enhancing its therapeutic potential across multiple cancer types [86] 7. **Goblet Trial**: The Goblet trial is a significant study evaluating Pelareorep in combination with gemcitabine, nab-paclitaxel, and atezolizumab, showing promising early results [34][35] 8. **Biomarker Insights**: Tumor-infiltrating lymphocyte expansion has been identified as a potential biomarker correlating with treatment response, suggesting a mechanism of action that enhances immune response [40][41] Other Important but Possibly Overlooked Content 1. **Durability of Response**: The durability of responses in patients treated with Pelareorep is a notable characteristic, indicating potential long-term benefits [15] 2. **Mechanism of Action**: Pelareorep induces endoplasmic reticulum stress in pancreatic cancer cells, leading to apoptosis, which supports its mechanism of action [20] 3. **Future Directions**: There is a strong interest in exploring Pelareorep in registration-enabling studies for first-line treatment in pancreatic cancer, given the promising efficacy and safety data [57][69] 4. **Cross-Tumor Potential**: Pelareorep has demonstrated efficacy across various tumor types, including breast and colorectal cancers, indicating its potential as a versatile therapeutic agent [86] This summary encapsulates the key insights and discussions from the Oncolytics Biotech webinar, focusing on the promising role of Pelareorep in treating pancreatic cancer and its potential applications in other cancers.

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.He leads the investing group Growth Stock Forum which features: a model portfolio of 15-2 ...

Preclinical-stage biotech company explores digital asset treasury opportunities to enhance capital efficiency while maintaining core focus on immunotherapy innovationLA PALMA, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies, today announced that it has initiated a strategic review to evaluate the potential inclusion of regulated digital asset strategies as part of it ...

ATLANTA, July 22, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) complied with federal securities laws. On July 22, 2025, Replimune announced it received a Complete Response Letter (“CRL”) from the FDA regarding the Biologics License Application (“BLA”) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. In the CRL, the FDA indicated “that the IGNYTE trial is not ...

Alnylam Pharmaceuticals (ALNY) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the s ...

ImmuCell Corporation (ICCC) has received a recommendation upgrade to “Outperform,” driven by consistent execution across its sales and gross margin profile, alongside emerging strategic optionality linked to its late-stage mastitis treatment, Re-Tain. The company's operational rebound, product mix strength and capacity scaling provide a solid base for continued performance, while developments in product innovation and regulatory progress introduce asymmetric upside potential.Price PerformanceICCC shares hav ...

Participation certificates (Partizipationsscheine) with a nominal value of CHF 0.001 each will replace the non-voting equity securities (Genussscheine). Reduction of the nominal value of the bearer shares (Inhaberaktien) from CHF 1 to CHF 0.001 in line with the nominal value of the new participation certificates.Participation certificates are economically equivalent to Genussscheine and will be listed on the SIX Swiss Exchange.Discontinuation of printed dividend vouchers and a further transition to intermed ...

Participation certificates (Partizipationsscheine) with a nominal value of CHF 0.001 each will replace the non-voting equity securities (Genussscheine). Reduction of the nominal value of the bearer shares (Inhaberaktien) from CHF 1 to CHF 0.001 in line with the nominal value of the new participation certificates.Participation certificates are economically equivalent to Genussscheine and will be listed on the SIX Swiss Exchange.Discontinuation of printed dividend vouchers and a further transition to intermed ...

There were warnings to the FDA about Sarepta before US regulators asked the company to halt shipments of its gene therapy https://t.co/ZZC0xgoUpS ...

ATLANTA, July 22, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed Alto Neuroscience, Inc. (“Alto” or the “Company”) (NYSE: ANRO). The lawsuit alleges that throughout the Class Period, and in the Company’s Offering Documents, Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information concerning Alto’s business, operations, and prospects, including allegations that: (i) ALTO-100 was less effective in treating MDD than Defenda ...